Get the Stockscreener App
35.83
7.05%
2.36
After Hours:
35.83
Septerna Inc stock is traded at $35.83, with a volume of 843.48K.
It is up +7.05% in the last 24 hours and up +15.02% over the past month.
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.
See More
Previous Close:
$33.47
Open:
$34.46
24h Volume:
843.48K
Relative Volume:
2.19
Market Cap:
$1.62B
Revenue:
$45.95M
Net Income/Loss:
$-48.88M
P/E Ratio:
-32.20
EPS:
-1.1129
Net Cash Flow:
$109.67M
1W Performance:
+6.99%
1M Performance:
+15.02%
6M Performance:
+35.67%
1Y Performance:
+230.23%
1-Day Range:
$34.43
$37.75
1-Week Range:
$32.91
$37.75
52-Week Range:
$10.62
$37.99
Septerna Inc Stock (SEPN) Company Profile
Name
Septerna Inc
Sector
Industry
Phone
650-338-3533
Address
250 EAST GRAND AVENUE, SUITE 65, SOUTH SAN FRANCISCO
Compare SEPN vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SEPN
Septerna Inc
|
35.83 | 1.51B | 45.95M | -48.88M | 109.67M | -1.1129 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.93 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.50 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Septerna Inc Stock (SEPN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-19-25 | Initiated | Raymond James | Strong Buy |
| Dec-15-25 | Initiated | Truist | Buy |
| Nov-14-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jun-23-25 | Initiated | H.C. Wainwright | Buy |
| Feb-18-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-19-24 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-19-24 | Initiated | JP Morgan | Overweight |
| Nov-19-24 | Initiated | TD Cowen | Buy |
| Nov-19-24 | Initiated | Wells Fargo | Overweight |
View All
Septerna Inc Stock (SEPN) Latest News
SEPN Q1 2026 Earnings: Smaller-than-expected loss as clinical-stage biotech advancesEarnings Yield Spread - dars.gov.et
Septerna's Chief People Officer Sold Nearly 12,000 Company Shares. What Does That Mean for Investors? - Yahoo Finance
Septerna's Chief People Officer Sold Nearly 12,000 Company Shares. What Does That Mean for Investors? - The Motley Fool
Septerna (SEPN) SVP Long exercises options and sells 3,333 shares in Rule 10b5-1 trades - Stock Titan
Is Septerna, Inc. (SEPN) Stock a Biotech Opportunity With a Potential First-in-Class Hypoparathyroidism Treatment? - Yahoo Finance
Septerna Inc. (SEPN) Slides 2.63% as Stock Tests Key Support Near $32Max Pain Level - dars.gov.et
Analysts Offer Insights on Technology Companies: Septerna, Inc. (SEPN) and Strategy (MSTR) - The Globe and Mail
SEPN Maintained by Guggenheim -- Price Target Lowered to $45.00 - GuruFocus
Truist Securities Adjusts Septerna Price Target to $43 From $35, Maintains Buy Rating - marketscreener.com
SEPN Maintains Buy RatingPrice Target Raised to $43.00 by Tru - GuruFocus
SEPN Reiterated by HC Wainwright & Co. -- Price Target Maintained at $40 - GuruFocus
Septerna (SEPN) Is Down 7.1% After Broad Russell Index Additions Has The Bull Case Changed? - simplywall.st
Analysts Are Bullish on Top Technology Stocks: Akamai (AKAM), Procore Technologies (PCOR) - The Globe and Mail
Septerna stock maintained at Buy by H.C. Wainwright after rival setback - Investing.com
Guggenheim cuts Septerna stock price target to $45 on CSU study risk - Investing.com
H.C. Wainwright Maintains Septerna(SEPN.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Truist raises Septerna stock price target to $43 on hypoparathyroidism outlook - Investing.com
5 Best Up and Coming Pharmaceutical Stocks to Buy Now - Insider Monkey
Septerna, Inc. Files 8-K Detailing Annual Meeting Results and Company Information – June 2026 - Minichart
Septerna chief people officer Samira Shaikhly sells $76,622 in stock - Investing.com UK
Form 4 Septerna Inc For: 30 June By Investing.com - Investing.com UK
Septerna (NASDAQ: SEPN) director-linked funds get 15,000-share option - Stock Titan
Septerna chief people officer Samira Shaikhly sells $76,622 in stock By Investing.com - Investing.com South Africa
Septerna (SEPN) CPO exercises options and sells 2,178 shares - Stock Titan
Septerna (SEPN) director Shalini Sharp receives stock options on 15,000 shares - Stock Titan
Septerna (SEPN) director Abraham Bassan receives grant of 15,000 stock options - Stock Titan
Septerna (SEPN) director granted 15,000 options for RA Capital funds - Stock Titan
Septerna (NASDAQ: SEPN) 2026 meeting elects directors and backs EY as auditor - Stock Titan
Cantor Fitzgerald Maintains Septerna(SEPN.US) With Buy Rating, Raises Target Price to $60 - Moomoo
Is Septerna a Stock to Sell After an Insider Let Go of 15,000 Shares? - Yahoo Finance
ETFs Investing in Septerna, Inc. Stocks - TradingView
Septerna Inc. (SEPN) Drops 8.4%: Key Support and Resistance Levels in FocusTick Index - dars.gov.et
Septerna, Inc.(NasdaqGM: SEPN) added to Russell 2000 Growth Benchmark - marketscreener.com
Septerna, Inc.(NasdaqGM: SEPN) added to Russell 3000E Growth Benchmark - marketscreener.com
SEPN Q1 2026 Earnings: EPS Beat Signals Efficient Cash ManagementDividend Growth Analysis - dars.gov.et
Septerna, Inc.(NasdaqGM: SEPN) added to Russell 2500 Growth Benchmark - marketscreener.com
SEPN Q1 2026 Earnings: Narrower-than-Expected Loss Drives Stock RallyMargin Improvement Report - dars.gov.et
Form 144 SEPTERNA For: 26 June By Investing.com - Investing.com South Africa
SEPN (NASDAQ) insider sale: JAE KIM sells 94,339 shares under Rule 144 - Stock Titan
Septerna obtains promising preclinical results with SEP-479 for hypoparathyroidism - BioWorld News
Septerna Inc (SEPN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Septerna, Inc. Actuals & Estimates (NASDAQ:SEPN) - TradingView
Septerna, Inc. (SEPN) reports Q1 loss, tops revenue estimates - MSN
SEPN Forecast — Price Target — Prediction for 2027 - TradingView
Form 4 Septerna Inc For: 24 June By Investing.com - Investing.com UK
Septerna SVP, drug discovery, sells $532,581 in stock By Investing.com - Investing.com South Africa
Septerna SVP, drug discovery, sells $532,581 in stock - Investing.com
Septerna (SEPN) SVP sells 15,000 shares under 10b5-1 plan - Stock Titan
Septerna stock hits all-time high at 37.32 USD By Investing.com - Investing.com South Africa
Septerna stock hits all-time high at 37.32 USD - Investing.com
Septerna Inc Stock (SEPN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Septerna Inc Stock (SEPN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Long Daniel D. | SVP, Drug Discovery |
Jul 01 '26 |
Sale |
34.36 |
3,333 |
114,528 |
96,412 |
| Shaikhly Samira | Chief People Officer |
Jun 29 '26 |
Option Exercise |
6.81 |
2,178 |
14,832 |
2,971 |
| Shaikhly Samira | Chief People Officer |
Jun 29 '26 |
Sale |
35.18 |
2,178 |
76,622 |
793 |
1.18%
2.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):